Pazopanib is a multitargeted tyrosine kinase inhibitor that inhibits angiogenesis pathways, namely VEGF, and has shown significant effect on tumor vascular density, viability, and volume in mice with chondrosarcoma xenografts [8]. Here, VEGFA is linked to chondrosarcoma.